ISRG

In the past six months (April to October 2026), Intuitive Surgical's stock experienced several notable events. The Q1 2026 earnings release on April 21, 2026, reported an EPS of $2.280 USD, leading to a +7.16% stock increase. The annual shareholders' meeting was held on April 30, 2026. Despite strong Q2 2026 financial results on July 16, 2026, with an EPS of $2.80 and revenue of $2.89 billion, the stock dropped approximately 14.2% due to muted full-year guidance for da Vinci procedure growth and concerns about increased competition. Six days later, the FDA cleared Johnson & Johnson's Ottava robot, further contributing to the stock's decline, following Medtronic's Hugo system clearance last year. A collaboration with Deion 'Coach Prime' Sanders on July 27, 2026, to raise patient awareness resulted in a +5.73% stock increase, while sharing a vision for AI-enabled healthcare on July 23, 2026, led to a -2.54% movement. A new meta-analysis on September 8, 2026, showing improved patient outcomes with da Vinci surgery, resulted in a +0.88% stock increase. Over the past 12 months, insiders sold $93.4 million worth of shares, coinciding with a 6.1% stock decline. Despite volatility, analysts maintain a 'Moderate Buy' rating with an average price target of $502.53, indicating an 18.5% upside, and institutional buying has increased.